{"result": "(\"entity\"<|>DOLOR ABDOMINAL<|>EVENT<|>DOLOR ABDOMINAL is the symptom that the 56-year-old male patient presented with, indicating a potential medical issue.)\n##\n(\"entity\"<|>HIPERTENSIÓN<|>EVENT<|>HIPERTENSIÓN is a chronic condition that the patient has, which is being managed with medication.)\n##\n(\"entity\"<|>ANALGESIA<|>EVENT<|>ANALGESIA refers to the pain management strategies employed for the patient during his hospital stay.)\n##\n(\"entity\"<|>CLORURO MÓRFICO<|>EVENT<|>CLORURO MÓRFICO is the medication used for pain relief in the patient.)\n##\n(\"entity\"<|>TC ABDOMINAL<|>EVENT<|>TC ABDOMINAL refers to the abdominal CT scan performed to assess the patient's condition.)\n##\n(\"entity\"<|>PCR<|>EVENT<|>PCR is a laboratory test result indicating inflammation in the patient's body.)\n##\n(\"entity\"<|>GLUCEMIA<|>EVENT<|>GLUCEMIA refers to the blood sugar levels monitored in the patient, which are relevant to his diabetes management.)\n##\n(\"relationship\"<|>VARÓN DE 56 AÑOS<|>DOLOR ABDOMINAL<|>The 56-year-old male patient presented with abdominal pain, which is a significant symptom of his condition.<|>8)\n##\n(\"relationship\"<|>VARÓN DE 56 AÑOS<|>HIPERTENSIÓN<|>The 56-year-old male patient has a history of hypertension, which is relevant to his overall health status.<|>5)\n##\n(\"relationship\"<|>CIRUGÍA GENERAL<|>ANALGESIA<|>The General Surgery department is responsible for managing the patient's analgesia during his treatment.<|>6)\n##\n(\"relationship\"<|>CIRUGÍA GENERAL<|>TC ABDOMINAL<|>The General Surgery department requested an abdominal CT scan to evaluate the patient's condition.<|>7)\n##\n(\"relationship\"<|>VARÓN DE 56 AÑOS<|>CLORURO MÓRFICO<|>The 56-year-old male patient was administered cloruro mórfico for pain management.<|>8)\n##\n(\"relationship\"<|>VARÓN DE 56 AÑOS<|>GLUCEMIA<|>The blood sugar levels (glucemia) of the 56-year-old male patient are being monitored due to his diabetes.<|>5)\n##\n(\"relationship\"<|>CIRUGÍA GENERAL<|>PCR<|>The General Surgery department is monitoring the patient's PCR levels as part of his clinical evaluation.<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ---\nhan mostrado el beneficio de introducir NE entre las 48 y 72 h del ingreso, así como una mayor morbilidad asociada a la introducción precoz de NP. En el presente caso clínico se revisa el manejo realizado, y se compara con las pautas indicadas en las últimas guías clínicas.\n\n## Caso clínico\n\n### Anamnesis URGENCIAS\n\n**Motivo consulta:** Varón de 56 años con dolor abdominal.\n\n**Antecedentes personales:** Ex fumador. Niega consumo alcohol de modo habitual. Hipertensión y diabetes mellitus tipo 2 no insulinotratado.\n\n**IQ previas:** hemangioma cerebeloso.\n\n**Medicación previa:** Enalapril 5 mg: (1-0-0) y Sitagliptina/metformina 50/1000 (1-0-1).\n\n**Anamnesis:** Refiere epigastralgia de inicio súbito tras el desayuno, muy intensa, con importante cortejo vegetativo. Dolor opresivo, no irradiado. Disnea en los picos de mayor dolor. Nauseas y vómitos acompañantes. Sin alteración del ritmo intestinal ni características de las heces. Sin fiebre termometrada ni distermia. Remitido desde urgencias ambulatorias para descartar IAM.\n\n**Exploración física:** Pálido y sudoroso. Quebrantamiento del estado general. Temperatura 38.6ºC. PA 164/98 mm Hg con 112 lpm rítmico. Abdomen blando y depresible, dolor y defensa a la palpación en hipocondrio derecho. Murphy positivo. No se palpan megalias.\n\n**Laboratorio:**\nHemograma: Serie roja normal, Leu 18.000 con desviación izquierda.\nFunción renal e iones normales. Glucemia 290 mg/dl, GOT 159 UI/L, GPT 208 UI/L, Amilasa 690, Troponina alta sensibilidad normal, PCR 32.\n\n**Exploraciones complementarias:**\n\n**TC abdominal:**\nHígado normal.\nVesícula biliar distendida (9.3x4 cm) con tenue realce parietal, que pudiera corresponder con colecistitis. Páncreas de aspecto globuloso a nivel de la cabeza y del cuello pancreático, con adecuado realce de todo su parénquima, apreciando aumento de densidad con reticulación de la grasa peri pancreática, así como moderada cantidad de líquido peri pancreático. Sugestivo de pancreatitis aguda edematosa en evolución, a correlacionar con parámetros clínico analíticos.\n---\nDía +1. Ingresa en CIRUGÍA GENERAL.\nAl ingreso (24 horas después) constantes estables. Muy mal control del dolor, precisa analgésicos extra a la perfusión. Dolor epigástrico que no se irradia, leves molestias en hipocondrio derecho, sin irritación, Murphy negativo.\n\nAnalítica: empeoramiento de la coagulación, con elevación de PCR, amilasa y transaminasas.\n\nSolicitan nuevo TC, similar al previo. Se modifica analgesia y se solicita a Farmacia NPT así como colocación de vía central (DRUM en cava superior). Se solicita interconsulta a Endocrinología y Nutrición en este momento.\n\nEvolución:\nVista analítica: 14.500 leucocitos/mmc (en descenso) con neutrofilia del 90,2%. 139.000 plaquetas/mmc (previamente normales). TP 56%. Función renal e iones normales. Bilirrubina total 2,4 mg/dL (directa 1,1 mg/dL).\n\nGOT 55 UI/L, GPT 112 UI/L, amilasa en descenso (190 UI/L). PCR 288 mg/L, PCT 0,6 ng/mL.\n\nMejor control del dolor con la perfusión de cloruro mórfico.\n\nDrum en cava superior.\n\nDía +2. IC Endocrinología y Nutrición (48h tras el ingreso).\nPaciente de 56 años que ingresa por sospecha de pancreatitis hace dos días, iniciada ayer NPT.\n\nAnamnesis: DM tipo 2 con buen control ambulatorio según Hb A1c (6.5%) en tratamiento habitual con inh DPPIV + metformina, sin complicaciones micro ni macroangiopáticas conocidas.\n\nEn el momento actual no refiere mucho dolor (desde que está con cloruro mórfico), leves molestias solamente. Polidipsia. No refiere pérdida de peso, ingesta normal hasta hace dos días.\n\nExploración física: TA 153/95 mmHg FC 117 lpm Tª 37.9º. SatO2 91%. Glucemias en 230-270 mg/dl. Peso 90 kg - Talla 171 cm - IMC 30 kg/m2.\n\nBuen estado general, eupneico en reposo. Tonos cardíacos rítmicos sin soplos. Murmullo vesicular fisiológico sin\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>CIRUGÍA GENERAL<|>ORGANIZATION<|>CIRUGÍA GENERAL is the department where the patient was admitted for surgical evaluation and management of suspected pancreatitis.)\n##\n(\"entity\"<|>ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>ENDOCRINOLOGÍA Y NUTRICIÓN is the department that was consulted for the patient's diabetes management and nutritional support.)\n##\n(\"entity\"<|>PANCREATITIS AGUDA EDEMATOSA<|>EVENT<|>PANCREATITIS AGUDA EDEMATOSA is the medical condition diagnosed in the patient, characterized by inflammation of the pancreas.)\n##\n(\"entity\"<|>VARÓN DE 56 AÑOS<|>PERSON<|>A 56-year-old male patient presenting with abdominal pain and suspected pancreatitis.)\n##\n(\"entity\"<|>HEMANGIOMA CEREBELOSO<|>EVENT<|>HEMANGIOMA CEREBELOSO is a previous medical condition of the patient, indicating a history of brain tumor.)\n##\n(\"entity\"<|>DIABETES MELLITUS TIPO 2<|>EVENT<|>DIABETES MELLITUS TIPO 2 is a chronic condition affecting the patient's blood sugar levels, which is being managed with medication.)\n##\n(\"entity\"<|>ENALAPRIL<|>EVENT<|>ENALAPRIL is a medication the patient was taking for hypertension.)\n##\n(\"entity\"<|>SITAGLIPTINA/METFORMINA<|>EVENT<|>SITAGLIPTINA/METFORMINA is a combination medication used by the patient to manage diabetes.)\n##\n(\"relationship\"<|>VARÓN DE 56 AÑOS<|>PANCREATITIS AGUDA EDEMATOSA<|>The 56-year-old male patient was diagnosed with acute edematous pancreatitis after presenting with abdominal pain.<|>8)\n##\n(\"relationship\"<|>VARÓN DE 56 AÑOS<|>DIABETES MELLITUS TIPO 2<|>The 56-year-old male patient has a history of type 2 diabetes, which is relevant to his current medical management.<|>5)\n##\n(\"relationship\"<|>VARÓN DE 56 AÑOS<|>HEMANGIOMA CEREBELOSO<|>The 56-year-old male patient has a previous medical history of cerebellar hemangioma, which may impact his overall health status.<|>3)\n##\n(\"relationship\"<|>CIRUGÍA GENERAL<|>PANCREATITIS AGUDA EDEMATOSA<|>The department of General Surgery is involved in the management of the patient's acute edematous pancreatitis.<|>7)\n##\n(\"relationship\"<|>ENDOCRINOLOGÍA Y NUTRICIÓN<|>DIABETES MELLITUS TIPO 2<|>The department of Endocrinology and Nutrition was consulted for the management of the patient's type 2 diabetes.<|>6)\n##\n(\"relationship\"<|>CIRUGÍA GENERAL<|>ENDOCRINOLOGÍA Y NUTRICIÓN<|>The departments of General Surgery and Endocrinology and Nutrition are collaborating on the patient's care due to his complex medical condition.<|>4)\n<|COMPLETE|>"}]}